A-371 Comparative Evaluation of POCT Based Lysophosphatidylcholine Measurement

Abstract Background Lysophosphatidylcholine (LPC), also referred to as lysolecithin, is a phospholipid intermediate whose concentrations have been correlated with such diseases as cancer, artherosclerosis and diabetes. Recently, serum LPC concentrations have been reported to be candidate biomarker for bacterial infection and sepsis. In this study, we evaluated the comparative performance of the point-of-care test (POCT) measurement of LPC using CareBuddy Multi Analyzer. Methods A total of 120 serum samples were analyzed for LPC by enzymatic spectrophotometry (CareBuddy Multi analyzer, CareBuddy catridge) and mass spectrometry based method (TSQ Altis LC/MS/MS) as the reference method. Additionally, subset of samples with enough remnant volumes were assessed for PCT and CRP using electrochemiluminescence immunoassay (Roche Cobas e801, Roche Elecsys BRAHMS PCT) and immunoturbidimetric assay (Roche Cobas c702, Sekisui Nanopia CRP), respectively. The equivalence and correlation among the methods were evaluated using linear regression analysis. Results The LPC measurement by POCT analyzer showed high correlations with the LC-MS based reference method (y = 1.02x + 1.26). The LPC measurement by POCT showed correlation coefficient for PCT (Pearson's r = −0.316) and CRP (Pearson's r = −0.618). Upon applying clinical cutoffs for qualitative result, LPC POCT measurement showed good agreements to each reference methods. Conclusion In summary, our results suggest that the quantitative measurement for LPC via POCT device in human serum samples possess possible clinical feasibility as a novel sepsis biomarker.